Cargando…
Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation
Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake. In patients with type 2 diabetes (T2D), concurrent NAFLD might increase the risk...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017161/ https://www.ncbi.nlm.nih.gov/pubmed/27612024 http://dx.doi.org/10.1038/srep33102 |
_version_ | 1782452694173089792 |
---|---|
author | Ye, Jia-Hung Chao, Jung Chang, Ming-Ling Peng, Wen-Huang Cheng, Hao-Yuan Liao, Jiunn-Wang Pao, Li-Heng |
author_facet | Ye, Jia-Hung Chao, Jung Chang, Ming-Ling Peng, Wen-Huang Cheng, Hao-Yuan Liao, Jiunn-Wang Pao, Li-Heng |
author_sort | Ye, Jia-Hung |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake. In patients with type 2 diabetes (T2D), concurrent NAFLD might increase the risk of chronic kidney disease and the mortality rate. Although several studies have examined the effectiveness of pentoxifylline (PTX) in NAFLD treatment, no results are available to verify the effectiveness of PTX in treating T2D associated with NAFLD. In this study, we developed a combined high-fat diet-induced obesity and low-dose streptozocin-induced hyperglycaemia mouse model to mimic the concurrent NAFLD and T2D pathological condition. By combining physiological assessments, pathological examinations, metabolomics studies on blood, urine, and liver, and measurements of gene and protein expression, we elucidated the effectiveness and the underlying mechanism of action of PTX in the hyperglycaemic and dyslipidaemic mice. Our results revealed that PTX ameliorated NAFLD in the hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. Furthermore, the glycolysis pathway and branched-chain amino acid-related pathways in these mice were restored by PTX. |
format | Online Article Text |
id | pubmed-5017161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50171612016-09-12 Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation Ye, Jia-Hung Chao, Jung Chang, Ming-Ling Peng, Wen-Huang Cheng, Hao-Yuan Liao, Jiunn-Wang Pao, Li-Heng Sci Rep Article Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake. In patients with type 2 diabetes (T2D), concurrent NAFLD might increase the risk of chronic kidney disease and the mortality rate. Although several studies have examined the effectiveness of pentoxifylline (PTX) in NAFLD treatment, no results are available to verify the effectiveness of PTX in treating T2D associated with NAFLD. In this study, we developed a combined high-fat diet-induced obesity and low-dose streptozocin-induced hyperglycaemia mouse model to mimic the concurrent NAFLD and T2D pathological condition. By combining physiological assessments, pathological examinations, metabolomics studies on blood, urine, and liver, and measurements of gene and protein expression, we elucidated the effectiveness and the underlying mechanism of action of PTX in the hyperglycaemic and dyslipidaemic mice. Our results revealed that PTX ameliorated NAFLD in the hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. Furthermore, the glycolysis pathway and branched-chain amino acid-related pathways in these mice were restored by PTX. Nature Publishing Group 2016-09-09 /pmc/articles/PMC5017161/ /pubmed/27612024 http://dx.doi.org/10.1038/srep33102 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Ye, Jia-Hung Chao, Jung Chang, Ming-Ling Peng, Wen-Huang Cheng, Hao-Yuan Liao, Jiunn-Wang Pao, Li-Heng Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation |
title | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation |
title_full | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation |
title_fullStr | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation |
title_full_unstemmed | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation |
title_short | Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation |
title_sort | pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017161/ https://www.ncbi.nlm.nih.gov/pubmed/27612024 http://dx.doi.org/10.1038/srep33102 |
work_keys_str_mv | AT yejiahung pentoxifyllineamelioratesnonalcoholicfattyliverdiseaseinhyperglycaemicanddyslipidaemicmicebyupregulatingfattyacidboxidation AT chaojung pentoxifyllineamelioratesnonalcoholicfattyliverdiseaseinhyperglycaemicanddyslipidaemicmicebyupregulatingfattyacidboxidation AT changmingling pentoxifyllineamelioratesnonalcoholicfattyliverdiseaseinhyperglycaemicanddyslipidaemicmicebyupregulatingfattyacidboxidation AT pengwenhuang pentoxifyllineamelioratesnonalcoholicfattyliverdiseaseinhyperglycaemicanddyslipidaemicmicebyupregulatingfattyacidboxidation AT chenghaoyuan pentoxifyllineamelioratesnonalcoholicfattyliverdiseaseinhyperglycaemicanddyslipidaemicmicebyupregulatingfattyacidboxidation AT liaojiunnwang pentoxifyllineamelioratesnonalcoholicfattyliverdiseaseinhyperglycaemicanddyslipidaemicmicebyupregulatingfattyacidboxidation AT paoliheng pentoxifyllineamelioratesnonalcoholicfattyliverdiseaseinhyperglycaemicanddyslipidaemicmicebyupregulatingfattyacidboxidation |